2023年11月6日 · Tremelimumab is used in adults to treat a certain type of liver cancer and lung cancer. Tremelimumab may be used in combination with other cancer treatments when the …

On November 10, 2022, the Food and Drug Administration approved tremelimumab (Imjudo, AstraZeneca Pharmaceuticals) in combination with durvalumab (Imfinzi, AstraZeneca …

2022年6月6日 · The STRIDE regimen, a single dose of tremelimumab in combination with durvalumab, met the primary objective of statistically significant improvement in overall …

On October 21, 2022, the Food and Drug Administration approved tremelimumab (Imjudo, AstraZeneca Pharmaceuticals) in combination with durvalumab for adult patients with …

TREMELIMUMAB (tre mel IM ue mab) treats liver cancer and lung cancer. It works by helping your immune system slow or stop the spread of cancer cells. It is a monoclonal antibody. This …

2025年3月1日 · Tremelimumab-actl injection is used in combination with durvalumab to treat liver cancer that cannot be removed by surgery (unresectable hepatocellular carcinoma or uHCC).

Tremelimumab is an anti-CTLA-4 antibody used to treat unresectable hepatocellular carcinoma in combination with durvalumab. Tremelimumab, formerly known as ticilimumab, is a fully human …

Non-small cell lung cancer that has spread to other parts of the body and does not have an abnormal EGFR or ALK gene. It is used with durvalumab and platinum-based chemotherapy. …

Medscape - Hepatocellular carcinoma dosing for Imjudo (tremelimumab), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation …

Tremelimumab (tremelimumab-actl; IMJUDO^®), a cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) blocking antibody, is being developed by AstraZeneca, under license from …